CYCisem Yilmaz

Cisem Yilmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cisem Yilmaz has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study

    by Dilan Damla Ozturk, Hilmi Erdem Sumbul, Erdinc Gulumsek, Cigdem Erhan, Bektas Isik, Cisem Yilmaz, Cahit Dincer, Ahmet Gazi Mustan, Irfan Alisan, Mevlut Koc, et al.

    Background/Objectives: Diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in patients with type 2 diabetes mellitus (T2DM) and share common pathophysiological mechanisms. Although atorvastatin has been investigated for potential renal and hepatic effects, real-world evidence regarding its associations with both renal and hepatic surrogate markers remains limited. This study investigated the association between atorvastatin therapy and longitudinal changes in urinary albumin-to-creatinine ratio (UACR) and liver stiffness measured by vibration-controlled transient elastography (VCTE) in patients with T2DM. Methods: This retrospective observational study included 612 patients with T2DM who were categorized into three groups according to atorvastatin treatment: no statin (n = 198), atorvastatin 10–20 mg/day (n = 205), and atorvastatin 40 mg/day (n = 209). UACR and liver stiffness were assessed at baseline and after six months. Between-group comparisons and multivariable linear regression analyses were performed to evaluate the independent association of atorvastatin therapy with changes in renal and hepatic surrogate markers. Results: Baseline UACR and liver stiffness were comparable among the three groups. During six months of follow-up, UACR increased in the no-statin group (+8.64 mg/g) but decreased significantly in the atorvastatin 10–20 mg (−27.68 mg/g) and 40 mg (−44.64 mg/g) groups (overall p < 0.001). Similarly, liver stiffness remained unchanged in the no-statin group (−0.02 kPa) but decreased by 0.42 kPa and 0.93 kPa in the atorvastatin 10–20 mg and 40 mg groups, respectively (overall p < 0.001). In multivariable models adjusted for baseline outcome values and relevant clinical covariates, both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group (all p < 0.001). Conclusions: Atorvastatin treatment intensity was associated with differences in six-month UACR and liver stiffness in patients with T2DM, with numerically greater reductions observed in the 40 mg/day group. These observational findings are hypothesis-generating and require confirmation in prospective studies before causal or long-term clinical benefits can be established.

  • Open Access

    C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide

    by İrfan Alişan, Kubilay Akbal, Çisem Yılmaz, Cahit Dinçer, Bektaş Işık, Ahmet Gazi Mustan, Fatih Necip Arıcı, Hüseyin Ali Öztürk, Hilmi Erdem Sümbül

    Background and Objective: To compare longitudinal changes in serum C-peptide during dipeptidyl peptidase-4 (DPP-4) inhibitor versus sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy in type 2 diabetes and to evaluate whether baseline C-peptide predicts glycemic response. Materials and Methods: This single-center retrospective new-user cohort study included 196 adults with type 2 diabetes who initiated a DPP-4 inhibitor (n = 99) or an SGLT2 inhibitor (n = 97) following a 12-month washout period. Baseline and follow-up HbA1c, plasma glucose, and fasting C-peptide measurements were assessed over a mean follow-up of 156 days. Glycemic response was defined as an HbA1c reduction of at least 1.0 percentage point. Multivariable linear and logistic regression analyses were performed, and receiver operating characteristic analysis evaluated the predictive performance of baseline C-peptide. Results: HbA1c decreased significantly in both groups, with no between-group difference in HbA1c reduction (1.03 ± 0.87 vs. 0.97 ± 0.83 percentage points; p = 0.650). C-peptide increased significantly in the DPP-4 inhibitor group but not in the SGLT2 inhibitor group (0.18 ± 0.44 vs. 0.03 ± 0.38 ng/mL; between-group p = 0.010). DPP-4 inhibitor therapy remained independently associated with higher follow-up C-peptide (adjusted β = 0.149; p = 0.013). Baseline C-peptide independently predicted glycemic response (adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001), whereas treatment class and the treatment-by-C-peptide interaction were not significant. Baseline C-peptide showed good discrimination for response (AUC = 0.805), with a Youden-derived exploratory cut-off of 2.33 ng/mL. Conclusions: DPP-4 inhibitors were associated with a greater increase in fasting C-peptide than SGLT2 inhibitors despite similar glycemic improvement; however, fasting C-peptide change alone should not be interpreted as direct evidence of improved or preserved β-cell function. Higher baseline C-peptide was associated with glycemic response in both treatment groups, although external validation is required before clinical application.

  • Open Access

    Changes in Symptoms and Lung Function During Three Months of Individually Tailored Inhaled Therapy in Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study

    by Bektas Isik, Hilmi Erdem Sumbul, Huseyin Ali Ozturk, Begum Seyda Avci, Erdinc Gulumsek, Merve Sumbul, Irfan Alisan, Ahmet Gazi Mustan, Fatih Necip Arici, Cisem Yilmaz, et al.

    Background. Randomised controlled trials have established what individual inhaled regimens can achieve in chronic obstructive pulmonary disease (COPD) under controlled conditions, but they recruit selected populations and enforce protocol-driven follow-up. How patients fare on regimens chosen individually for them in everyday care is less well characterised. Objective. To assess the change in symptoms and lung function over three months in a prospective cohort of patients with COPD whose inhaled treatment was tailored to the individual by the attending physician. Methods. Consecutive adults with stable, spirometrically confirmed COPD attending a single internal-medicine clinic were assessed at baseline and reassessed approximately three months later. Baseline regimens were short-acting beta2-agonist/short-acting muscarinic antagonist (SABA/SAMA), long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), LABA plus inhaled corticosteroid (ICS), LABA plus LAMA, or LABA plus LAMA plus ICS. The primary outcomes were the within-participant change in COPD Assessment Test (CAT) score and in forced expiratory volume in one second (FEV1) % predicted. Secondary outcomes were the proportion achieving the CAT minimal clinically important difference (MCID, defined as a reduction of at least two points), the proportion achieving a six-minute walk distance (6MWD) improvement of at least 30 m, change in modified Medical Research Council (mMRC) dyspnoea grade, body mass index–airflow obstruction–dyspnoea–exercise capacity (BODE) and age–dyspnoea–obstruction (ADO) indices, and clinical events. Paired changes were analysed with paired t-tests or Wilcoxon signed-rank tests and are reported with 95% confidence intervals (CIs). Results. Three hundred participants were enrolled. Recorded GOLD groups were A (n = 69), B (n = 158) and E (n = 73). Paired CAT and FEV1 data were available for 276 (92.0%) and 257 (85.7%) participants, all of whom were reassessed between 84 and 98 days after baseline (median 91 days). Across the cohort, mean CAT fell by 3.93 points (95% CI −4.43 to −3.44) and mean FEV1 rose by 2.20 percentage points (95% CI 1.78 to 2.63); one hundred and ninety-five of 276 participants (70.7%) reached the CAT MCID and 98 of 244 (40.2%) achieved a 6MWD gain of at least 30 m. Improvement was observed with every long-acting regimen. Participants receiving LABA + ICS improved by 4.18 CAT points (95% CI −5.24 to −3.12; p < 0.001) and 3.06 FEV1 percentage points (95% CI 2.16 to 3.95; p < 0.001), with 82.1% reaching the CAT MCID—a magnitude similar to that observed on LABA+LAMA. Participants on SABA/SAMA alone showed no improvement in either outcome. Sixty-three exacerbations, eleven hospitalisations and four cases of pneumonia occurred. Conclusions. During a reassessment interval of 84 to 98 days, patients with COPD receiving individually tailored long-acting inhaled therapy showed improvement in symptoms and lung function that exceeded the established MCID for the CAT, including patients treated with LABA+ICS. The study had no concurrent control group, no randomisation and no adjustment for baseline differences between regimens; the observed changes therefore describe the course of treated patients and cannot be attributed to any specific regimen.

  • Open Access

    Real-world treatment gaps in hypertension management: drug switching, prescribing patterns and apparent resistant hypertension – a retrospective observational study

    by Hilmi Erdem Sumbul, Ahmet Gazi Mustan, Bektas Isik, Huseyin Ali Ozturk, Fatih Necip Arici, Begüm Seyda Avci, Erdinc Gulumsek, Merve Sumbul, Dilan Damla Ozturk, Irfan Alisan, et al.

  • Open Access

    Diabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Study

    by İrfan Alisan, Ahmet Gazi Mustan, Bektas Isik, Fatih Necip Arıcı, Cahit Dinçer, Çisem Yılmaz, Mehmet Erdevir, Ahmet Altıntaş, Çiğdem Erhan, Merve Saracoglu Sumbul, et al.

    Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.

  • The Association between SGLT2 Inhibitors Use and the Risk of Contrast Induced Acute Kidney Injury in Patients with Type 2 Diabetes

    by Hüseyin Ali Öztürk, Erdinc Gulumsek, Dilan Damla Ozturk, Fatih Necip Arıcı, Begüm Şeyda Avci, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, İrfan Alişan, Cahit Dincer, et al.

    Aim: Contrast-induced acute kidney injury (CI-AKI) is associated with increased risk of morbidity and mortality and specific treatments are needed. In our study, we aimed to investigate the association of sodium-glucose cotransporter-2 inhibitors (SGLT2-I) use with the development of CI-AKI due to coronary angiography (CAG) in patients with DM. Methods: A total of 516 type 2 diabetes mellitus (DM) patients, including 250 SGLT2-I users and 266 non-SGLT2-I users, were included in our retrospective and cross-sectional study. Results: The study groups were divided into CI-AKI (+) and CI-AKI (-). SGLT2-I use was statistically significantly higher in the CI-AKI (-) group. Multivariate logistic regression analysis showed that SGLT2-I use reduced the probability of CI-AKI by 83.8%. Conclusion: Our findings suggest that SGLT2-Is may significantly reduce the risk of CI-AKI in diabetic patients undergoing CAG. In conclusion, the use of SGLT2-I may have a protective and preventive effect against the development of CI-AKI.


  • Open Access

    Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?

    by Hüseyin Ali Öztürk, Erdinc Gulumsek, Dilan Damla Ozturk, Fatih Necip Arıcı, Cigdem Erhan, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, Ugur Can Izlimek, Cahit Dincer, et al.

    Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened. In our study, we aimed to evaluate patients with HFpEF who were followed up in our internal medicine clinic. Methods: Our retrospective and cross-sectional study included 348 patients with HFpEF. Patients were evaluated according to laboratory, demographic, clinical, electrocardiographic and ultrasonographic findings. Results: Of the patients, 37.95% had diabetes mellitus, 23.3% had chronic kidney disease, 70.1% had hypertension and 59.2% had metabolic dysfunction-associated steatotic liver disease. The mean NT-proBNP level was 360.7 ± 13.7. Conclusion: We recommend that HFpEF, which is associated with increased cardiovascular mortality and morbidity in patients with CRMD, should be screened clinically and with NT-proBNP and evaluated with transthoracic echocardiography if necessary.

  • Open Access

    Proptosis is associated with thiol-disulfide in patients with Graves’ ophthalmopathy

    by Fettah Acibucu, Dilan Damla Öztürk, Cisem Kizildag, Muhammed Zubeyir Aslan, Erdinc Gulumsek, Merve Saracoglu Sumbul, Salim Neselioglu, Ozcan Erel, Suat Sen, Mehmet Bankir, et al.

    Objective: Graves’ ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves’ disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress. In our study, we compared the relationship between proptosis and SH-SS in patients diagnosed with GO. Materials and methods: In this prospective study, 40 recently diagnosed Graves’ disease patients with proptosis, 40 recently diagnosed Graves’ disease patients without GO and 30 healthy individuals with similar demographic characteristics were [...] ABSTRACT Objective: Graves’ ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves’ disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress. In our study, we compared the relationship between proptosis and SH-SS in patients diagnosed with GO. Materials and methods: In this prospective study, 40 recently diagnosed Graves’ disease patients with proptosis, 40 recently diagnosed Graves’ disease patients without GO and 30 healthy individuals with similar demographic characteristics were


  • Serum Elabela level is related to endoscopic activity index in patients with active ulcerative colitis

    by Erdinc Gulumsek, Hilmi Erdem Sumbul, Fatih Yesildal, Cisem Kizildag, Dilan Damla Ozturk, Begum Seyda Avci, Beytullah Aktas, Akkan Avci, Edip Bayrak, Adnan Tas, et al.

    Background In ulcerative colitis patients, Elabela levels and the relation of Elabela with laboratory parameters is unknown. Aim The purpose of this study was to investigate the serum Elabela levels in UC patients and its relationship with other clinical and laboratory findings. Methods Forty-three patients with UC and 40 healthy controls (group I) similar in age and gender were included in the study. Routine patient history, physical examination, and laboratory tests were followed by analysis of serum Elabela levels. Endoscopic activity index (EAI) of patients with UC was calculated. There were two groups of patients: those in remission (group II) and with active disease (group III). Results Groups I, II, and III had 40, 22, and 21 participants, respectively. Serum Elabela levels were found to be 3.32 ± 1.25 ng/mL in group I, 3.38 ± 0.88 ng/mL in group II, and 5.48 ± 1.61 ng/mL in group III. Comparing the serum Elabela levels, a statistically significant difference was found between three groups (p < 0.001). Serum Elabela level showed a significant and positive correlation with EAI, leukocyte count, and hs-CRP, while a negative correlation was found with hemoglobin levels in univariate analysis (p < 0.001, for each). In linear regression analysis, these parameters were found to be associated with EAI and hs-CRP (p = 0.049, β = 0.337, and p = 0.015, β = 0.396, respectively). Conclusion Elabela concentrations in patients with active UC was significantly higher and was associated with EAI and hs-CRP. Blood Elabela concentrations can be useful in the diagnosis and follow-up of patients with active UC.


  • Atypically located spider angioma

    by Şehmus Ölmez, Bünyamin Sarıtaş, Çisem Kzıldağ, Mehmet Kamil Mülayi̇m

    To the Editor, A spider angioma or spider naevus is a type of telangiectasis found slightly beneath the skin surface, often containing a central arteriole and many small vessels which radiate outwards like a spider's web. Applying pressure to the center of the lesion leads to fading of the lesion. Spider angioma is a common presentation of liver cirrhosis, especially alcoholic cirrhosis. Spider angiomas are found only in the distribution of the superior vena cava, and are thus commonly found on the face, neck, upper chest and upper arm. Spider angioma is rarely observed on hand (1, 2). Here, we report a a very rare case with spider angioma on back of hand. A 54-year-old male patient admitted to our clinic with icterus and ascites. The patient had a diagnosis of alcoholic liver cirrhosis one month before. On physical examination, he had icterus and ascites. He had spider angiomas on his back, neck and on the back of his right hand, just proximal to second metacarpophalangeal joint (Figure 1). The patient’s Child Turcotte Pugh score (CTP) and model for end stage liver disease (MELD) scores were 12 and 22, respectively. Abdomen ultrasound showed cirrhosis with massive ascites. Endoscopy revealed grade 1 esophageal varices and portal hypertensive gastropathy. The patient gave written consent regarding this article. Spider angioma appears frequently in alcoholic cirrhotic or noncirrhotic alcoholic liver diseases with deuteriation of liver functions. Although, the exact cause of SA is not known, there have been many theories of possible etiologic factors such as disturbance of sex hormones (increased level of luteinizing hormone, decreased level of testosterone and a higher estradiol/testosterone ratio), angiogenesis, vasodilation, alcohol abuse, hyperdynamic circulation state, and liver dysfunction[3, 4]. The number and size of SA are correlated with the degree of liver disease (1, 3, 4). Our patient was a heavy drinker and had alcoholic liver cirrhosis with high CTP and MELD score. Although, our patient had multiple telangiectasias, it is a very rare finding of SA, observed on back of hand.